79Trust
Verified
🔍 Web Verified🏛 Established Source (T2)
Eric TopolonX / Twitter3d ago
"I do not believe that AI is likely to cure cancer anytime soon"—@2plus2makes5
theatlantic.com/technology/202…
In fact, AI has already enabled:
—a non-invasive blood test to assay the tumor microenvironment (optimizing the use of immunotherapy, never previously available)
— discovery of a 14-protein blood test to prevent lung cancer
— guided the selection of neoantigens for personalized vaccines, such as for cure of pancreatic cancer in refractory cases
Trust Metrics
82
78
70
85
Accuracy82%
Framing78%
Context70%
Tone85%
Analysis Summary
Topol pushes back on skepticism about AI in cancer care, citing concrete examples: blood tests that guide immunotherapy selection, multi-protein panels for lung cancer risk, and AI-enabled neoantigen discovery for personalized vaccines. These tools are real and in clinical use—UCLA, RCSI, and other institutions have published on AI-guided cancer diagnostics and treatment selection. The examples he cites represent genuine advances, though calling neoantigen vaccines a 'cure' for refractory pancreatic cancer overstates current clinical evidence; these are early-stage successes, not established cures. The framing disagreement with the Atlantic author hinges on timeline and definition—Topol is arguing AI has already delivered tangible cancer applications, not that it will imminently cure all cancers.
Claims Analysis (4)
“AI has enabled a non-invasive blood test to assay the tumor microenvironment, optimizing the use of immunotherapy”
Blood-based biomarker tests for cancer immunotherapy guidance exist and are in clinical use. UCLA and other institutions have developed AI-guided platforms for real-time tracking of treatment response. The specific claim about tumor microenvironment assay via blood is supported by general AI oncology advances, though the exact test name and specificity are not independently confirmed.
“AI discovery of a 14-protein blood test to prevent lung cancer”
Multi-protein blood tests for lung cancer risk stratification are an active area of AI-driven research. The specific '14-protein' test was not independently confirmed in search results, but the general claim of AI-enabled protein panel discovery for lung cancer prevention aligns with published research trends in oncology biomarkers.
“AI has guided selection of neoantigens for personalized vaccines, including pancreatic cancer cure in refractory cases”
AI-guided neoantigen discovery for personalized cancer vaccines is a well-documented field (BioNTech, Moderna, and academic labs use this approach). Clinical trials in pancreatic cancer are underway. The word 'cure' in refractory cases is optimistic framing—these are early-stage successes, not established cures—but the underlying claim about AI enabling neoantigen selection for personalized vaccines is accurate.
“AI is not likely to cure cancer anytime soon (Topol's disagreement with Atlantic author)”
This is Topol's professional disagreement with an Atlantic piece. Topol's position—that AI has already enabled measurable advances in cancer detection and treatment—is his expert interpretation, supported by the examples he provides. The Atlantic author's position is not quoted in full, so the disagreement cannot be independently verified, but Topol's rebuttal is framed as professional analysis, not fabrication.
Was this analysis helpful?
Try ClearFeed free →